Tag: Efgartigimod

The landscape of myasthenia gravis (MG) treatment has evolved beyond traditional immunosuppressants to include advanced, targeted injectable therapies. These newer options, including both subcutaneous injections and intravenous infusions, target specific components of the immune system to manage symptoms more effectively and improve quality of life.

Over the last few years, the treatment landscape for myasthenia gravis (MG) has been revolutionized with the arrival of new, targeted therapies, moving beyond broad immunosuppression. A major development includes the approval of several new medications that specifically target key immune pathways, providing more effective and precise treatment options for patients asking, 'What is the new medicine for myasthenia gravis?'.

Founded in 2008, argenx is a global immunology company with a primary focus on improving the lives of people living with severe autoimmune diseases by translating immunology breakthroughs into a portfolio of innovative antibody-based medicines. The key question, "What does argenx do?", is answered through its strategic focus on targeting the underlying biology of these conditions with its proprietary technology platforms.